Home About Us Our Technology News + Media Investor Relations Contact Us
Company Press Releases Publications


Company Press Releases                                                                               Back

CytoSorbents Launches New International CytoSorb® Therapy Product Website

Wednesday March 11, 2015

MONMOUTH JUNCTION, N.J., March 11, 2015 - CytoSorbents Corporation (NASDAQ CM: CTSO), a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to treat critically-ill and cardiac surgery patients in multiple countries worldwide, announced the international launch of its new CytoSorb® Therapy product website.

Available in English at http://www.cytosorb.com and in German at http://www.cytosorb-therapie.de, visitors can learn why CytoSorb® represents one of the most promising technologies to help control deadly inflammation in hospitalized patients, with the goal of saving lives and reducing the exorbitant costs of medical care.

Geared towards physicians and other healthcare professionals, the website explains how CytoSorb® safely reduces cytokines, toxins, and other inflammatory mediators as a proactive strategy to reign in an out-of-control whole body immune response that otherwise frequently leads to organ failure and death in common life-threatening conditions such as severe sepsis and septic shock, lung injury, trauma, burn injury, liver failure, and pancreatitis.

Users can also learn about how CytoSorb® Therapy is being applied intra-operatively and post-operatively in cardiac surgery in order to try to prevent or treat post-operative complications such as kidney injury, lung failure, and a maladaptive post-op SIRS (systemic inflammatory response syndrome) response.

The website hosts a wealth of centralized information, including:

  • Information on CytoSorb® - its mechanism of action, the scientific rationale behind why and how it is being used, technical data on the technology, and physician testimonials
  • A detailed focus on the growing number of enrolling clinical trials and investigator-initiated studies using CytoSorb® in a wide variety of applications, with many more on the way
  • Literature references and detailed summaries of recently published peer-reviewed case reports and other studies, with the intent of teaching physicians how CytoSorb® Therapy is being successfully used today
  • A description and link to the International CytoSorb Registry, a Good Clinical Practice (GCP) quality repository for CytoSorb® treatment data from all over the world
  • A calendar of medical conferences, company-sponsored research symposia, and exhibitions where healthcare providers, distributors, and strategic partners can meet and talk with the company
  • A list of distributor contact information so that interested physicians worldwide can find out how to order CytoSorb®
  • Contact information of our direct sales team and customer support and service

We cordially invite medical professionals to sign up for our periodic CytoSorb® newsletter in the lower banner of the website.

About CytoSorbents Corporation

CytoSorbents Corporation is a critical care focused immunotherapy company using blood purification to control severe inflammation -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union and marketed in 29 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com/

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2014, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1910667.

Please Click to Follow us on Facebook and Twitter


Company Contact
Amy Vogel
CytoSorbents Medical, Inc
Investor Relations
(732) 329-8885 ext. *825
Investor Contact
Lee Roth
The Ruth Group
(646) 536-7012
Public Relations Contact
Melanie Sollid-Penton
The Ruth Group
(646) 536-7023
Source: CytoSorbents Corporation

Home | Career Opportunities | Contact Us
© 2014 CytoSorbents Incorporated All Rights Reserved